Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yasunari Yamashita"'
Autor:
Yasunari Yamashita, Gaku Inoue, Yoichi Nozaki, Rina Kitajima, Kiyoshi Matsubara, Takeshi Horii, Junichi Mohri, Koichiro Atsuda, Hajime Matsubara
Publikováno v:
BMC Research Notes, Vol 14, Iss 1, Pp 1-6 (2021)
Abstract Objective In the diabetes treatment policy after the Kumamoto Declaration 2013, it is difficult to accurately predict the incidence of complications in patients using the JJ risk engine. This study was conducted to develop a prediction equat
Externí odkaz:
https://doaj.org/article/61b1872f126e424088b10679d51a780c
Publikováno v:
BMC Research Notes, Vol 14, Iss 1, Pp 1-5 (2021)
Abstract Objective In 2018, we conducted a retrospective survey using the medical records of 484 patients with type 2 diabetes. The observed value of coronary heart disease (CHD) incidence after 5 years and the predicted value by the JJ risk engine a
Externí odkaz:
https://doaj.org/article/98811675104a42e7b9b3eb11387d1e17
Publikováno v:
BMC Research Notes
BMC Research Notes, Vol 14, Iss 1, Pp 1-5 (2021)
BMC Research Notes, Vol 14, Iss 1, Pp 1-5 (2021)
Objective In 2018, we conducted a retrospective survey using the medical records of 484 patients with type 2 diabetes. The observed value of coronary heart disease (CHD) incidence after 5 years and the predicted value by the JJ risk engine as of 2013
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b223f8f23d8a14cba29edde63963454b
https://doi.org/10.1186/s13104-021-05508-9
https://doi.org/10.1186/s13104-021-05508-9
Objective: The JJ risk engine, developed in 2012, is an algorithm that predicts the 19 incidence of diabetes complications that may develop after 5 to 10 years. However, 20 studies validating the JJ risk engine have not yet been reported;we aimed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0fde3a5e1f69f02a1e834ad45138902
https://doi.org/10.21203/rs.3.rs-132006/v1
https://doi.org/10.21203/rs.3.rs-132006/v1
Autor:
Ryo Mitsugi, Mitsutoshi Asakura, Hideaki Fujii, Kenichiro Nagai, Koichiro Atsuda, Tomoo Itoh, Ryoichi Fujiwara, Yasunari Yamashita
Publikováno v:
Drug Metabolism and Pharmacokinetics. 31:201-209
Vildagliptin is an inhibitor of dipeptidyl peptidase-4 that is used for the treatment of type 2 diabetes mellitus. While vildagliptin can induce hepatic dysfunction in humans, the molecular mechanism has not been determined yet. Recent studies indica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea1574ef7650f882c30badcefe006b65
https://doi.org/10.1016/j.dmpk.2016.02.004
https://doi.org/10.1016/j.dmpk.2016.02.004